Upadhyaya N B, Childs K D, Neiger R, Caudle M R
Department of Obstetrics and Gynecology, University of Tennessee Medical Center at Knoxville 37920, USA.
J Reprod Med. 1999 Apr;44(4):363-6.
To study the safe use of Dilapan at term for ripening the unfavorable cervix in an outpatient setting.
Prospective review of cervical ripening with Dilapan in women at term gestation. Such women were assigned to either outpatient or inpatient cervical ripening with Dilapan.
Twenty-one patients were assigned to each group. The length of induction was similar between women who had ambulatory cervical ripening and hospitalized patients (11 +/- 7 vs. 14 +/- 7 hours, respectively), and the rates of chorioamnionitis, endometritis and nonreassuring fetal heart rate tracings were also similar. However, the average length of hospitalization was significantly shorter for those who had ambulatory ripening as compared to those who were hospitalized (51 +/- 27 vs. 70 +/- 20 hours, respectively; P < .0007).
The use of Dilapan for cervical ripening at term in an ambulatory setting is safe and effective and may decrease the overall hospitalization time and cost.
研究在门诊环境中使用狄拉潘(Dilapan)足月促宫颈成熟的安全性。
对足月妊娠妇女使用狄拉潘促宫颈成熟进行前瞻性评估。这些妇女被分配接受门诊或住院使用狄拉潘促宫颈成熟。
每组分配21例患者。门诊促宫颈成熟的妇女与住院患者的引产时间相似(分别为11±7小时和14±7小时),绒毛膜羊膜炎、子宫内膜炎和胎儿心率异常的发生率也相似。然而,门诊促宫颈成熟患者的平均住院时间明显短于住院患者(分别为51±27小时和70±20小时;P<.0007)。
在门诊环境中使用狄拉潘足月促宫颈成熟是安全有效的,并且可能缩短总体住院时间和降低费用。